Subcellular targeting strategies for drug design and delivery

Nature Reviews Drug Discovery

Volumn 9, Issue 1, 2010, Pages 29-42

  Rajendran, Lawrence ^a,b   Knölker, Hans Joachim ^c   Simons, Kai ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIVIRUS AGENT; BETA GLUCOSIDASE; BETA N ACETYLHEXOSAMINIDASE; BETA SECRETASE INHIBITOR; CERAMIDE; CISPLATIN; CLATHRIN; DENILEUKIN DIFTITOX; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ENFUVIRTIDE; FOLATE RECEPTOR; FOLIC ACID; G PROTEIN COUPLED RECEPTOR; GAMITRINIB DERIVATIVE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; INTERLEUKIN 13; INTERLEUKIN 4; MACROGOL; NANOPARTICLE; PEPTOID; POLYMER; SMALL INTERFERING RNA; TRANSFERRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

CELL MEMBRANE; CELL NUCLEUS; CYTOSOL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SPECIFICITY; DRUG TARGETING; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ENDOSOME; GOLGI COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRACELLULAR SPACE; LIPID RAFT; LYSOSOME; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIMIAN VIRUS 40; VIRAL GENE DELIVERY SYSTEM; VIRUS ENTRY; VIRUS INHIBITION;

ANIMALS; BIOLOGICAL TRANSPORT; CELL MEMBRANE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; SUBCELLULAR FRACTIONS;

EID: 74049133619     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2897     Document Type: Review

References (172)

1. Gershell, L. J. & Atkins, J. H. A brief history of novel drug discovery technologies. Nature Rev. Drug Discov. 2, 321-327 (2003).
2. Langer, R. Drug delivery. Drugs on target. Science 293, 58-59 (2001).
3. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001).
4. Rosen, H. & Abribat, T. The rise and rise of drug delivery. Nature Rev. Drug Discov. 4, 381-385 (2005).
5. Blobel, G. Protein targeting (Nobel lecture). Chembiochem 1, 86-102 (2000).
6. Gruenberg, J. & van der Goot, F. G. Mechanisms of pathogen entry through the endosomal compartments. Nature Rev. Mol. Cell Biol. 7, 495-504 (2006).
7. Simons, K. & Ikonen, E. Functional rafts in cell membranes. Nature 387, 569-572 (1997).
8. Zerial, M. & McBride, H. Rab proteins as membrane organizers. Nature Rev. Mol. Cell Biol. 2, 107-117 (2001).
9. Grassme, H. et al. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem. 276, 20589-20596 (2001).
10. Heldin, C. H. Dimerization of cell surface receptors in signal transduction. Cell 80, 213-223 (1995).
11. Jordan, B. A. & Devi, L. A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399, 697-700 (1999).
12. Schwyzer, R. Membrane-assisted molecular mechanism of neurokinin receptor subtype selection. EMBO J. 6, 2255-2259 (1987).
13. Schwyzer, R. How do peptides interact with lipid membranes and how does this affect their biological activity? Braz. J. Med. Biol. Res. 25, 1077-1089 (1992).
14. Kholodenko, B. N., Brown, G. C. & Hoek, J. B. Diffusion control of protein phosphorylation in signal transduction pathways. Biochem. J. 350, 901-907 (2000).
15. Kholodenko, B. N., Hoek, J. B. & Westerhoff, H. V. Why cytoplasmic signalling proteins should be recruited to cell membranes. Trends Cell Biol. 10, 173-178 (2000).
16. Este, J. A. & Telenti, A. HIV entry inhibitors. Lancet 370, 81-88 (2007).
17. Reeves, J. D. & Piefer, A. J. Emerging drug targets for antiretroviral therapy. Drugs 65, 1747-1766 (2005).
18. Hildinger, M. et al. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J. Virol. 75, 3038-3042 (2001).
19. Melikyan, G. B., Egelhofer, M. & von Laer, D. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J. Virol. 80, 3249-3258 (2006).
20. Ingallinella, P. et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl Acad. Sci. USA 106, 5801-5806 (2009).
21. Miyauchi, K., Kim, Y, Latinovic, O., Morozov, V & Melikyan, G. B. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137, 433-444 (2009).
22. Boonyarattanakalin, S., Hu, J., Dykstra-Rummel, S. A., August, A. & Peterson, B. R. Endocytic delivery of vancomycin mediated by a synthetic cell surface receptor: rescue of bacterially infected mammalian cells and tissue targeting in vivo. J. Am. Chem. Soc. 129, 268-269 (2007).
23. Rajendran, L. et al. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science 320, 520-523 (2008).
24. Gripon, P., Cannie, I. & Urban, S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J. Virol. 79, 1613-1622 (2005).
25. Petersen, J. et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nature Biotech. 26, 335-341 (2008).
26. George, S. R., O'Dowd, B. F. & Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nature Rev. Drug Discov. 1, 808-820 (2002).
27. Gether, U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21, 90-113 (2000).
28. Covic, L., Gresser, A. L, Talavera, J., Swift, S. & Kuliopulos, A. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl Acad. Sci. USA 99, 643-648 (2002).
29. Covic, L, Misra, M., Badar, J., Singh, C. & Kuliopulos, A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nature Med. 8, 1161-1165 (2002).
30. Sheff, D. Endosomes as a route for drug delivery in the real world. Adv. Drug Deliv. Rev. 56, 927-930 (2004).
31. Pagano, R. E., Puri, V., Dominguez, M. & Marks, D. L. Membrane traffic in sphingolipid storage diseases. Traffic 1, 807-815 (2000).
32. Rajendran, L. et al. Alzheimer's disease β-amyloid peptides are released in association with exosomes. Proc. Natl Acad. Sci. USA 103, 11172-11177 (2006).
33. Sorkin, A. Cargo recognition during clathrin-mediated endocytosis: a team effort. Curr. Opin. Cell Biol. 16, 392-399 (2004).
34. Maxfield, F. R. & McGraw, T. E. Endocytic recycling. Nature Rev. Mol. Cell Biol. 5, 121-132 (2004).
35. Conner, S. D. & Schmid, S. L. Regulated portals of entry into the cell. Nature 422, 37-44 (2003).
36. Schmid, S. L. Clathrin-coated vesicle formation and protein sorting: an integrated process. Annu. Rev. Biochem. 66, 511-548 (1997).
37. Mukherjee, S., Ghosh, R. N. & Maxfield, F. R. Endocytosis. Physiol. Rev. 77, 759-803 (1997).
38. Sonnichsen, B., De Renzis, S., Nielsen, E., Rietdorf, J. & Zerial, M. Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11. J. Cell Biol. 149, 901-914 (2000).
39. Han, W., Zhang, T., Yu, H., Foulke, J. G. & Tang, C. K. Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol. Ther. 5, 1361-1368 (2006).
40. Miaczynska, M., Pelkmans, L. & Zerial, M. Not just a sink: endosomes in control of signal transduction. Curr. Opin. Cell Biol. 16, 400-406 (2004).
41. Sorkin, A. & Von Zastrow, M. Signal transduction and endocytosis: close encounters of many kinds. Nature Rev. Mol. Cell Biol. 3, 600-614 (2002).
42. Schenck, A. et al. The endosomal protein Appl1 mediates Akt substrate specificity and cell survival in vertebrate development. Cell 133, 486-497 (2008).
43. von Zastrow, M. & Sorkin, A. Signaling on the endocytic pathway. Curr. Opin. Cell Biol. 19, 436-445 (2007).
44. Miaczynska, M. et al. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell 11 6, 445-456 (2004).
45. Kermorgant, S. & Parker, P. J. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J. Cell Biol. 182, 855-863 (2008).
46. Bokel, C., Schwabedissen, A., Entchev, E., Renaud, O. & Gonzalez-Gaitan, M. Sara endosomes and the maintenance of Dpp signaling levels across mitosis. Science 314, 1135-1139 (2006).
47. Coumailleau, F., Furthauer, M., Knoblich, J. A. & Gonzalez-Gaitan, M. Directional Delta and Notch trafficking in Sara endosomes during asymmetric cell division. Nature 458, 1051-1055 (2009).
48. Schulz, R., Wehmeyer, A. & Schulz, K. Opioid receptor types selectively cointernalize with G protein-coupled receptor kinases 2 and 3. J. Pharmacol. Exp. Ther. 300, 376-384 (2002).
49. Smith, A. E. & Helenius, A. How viruses enter animal cells. Science 304, 237-242 (2004).
50. Marsh, M. & Helenius, A. Virus entry: open sesame. Cell 124, 729-740 (2006).
51. Sandvig, K. & van Deurs, B. Membrane traffic exploited by protein toxins. Annu. Rev. Cell Dev. Biol. 18, 1-24 (2002).
52. Mercer, J. & Helenius, A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320, 531-535 (2008).
53. Lamaze, C. et al. Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway. Mol. Cell 7, 661-671 (2001).
54. Grassart, A., Dujeancourt, A., Lazarow, P. B., Dautry-Varsat, A. & Sauvonnet, N. Clathrin-independent endocytosis used by the IL-2 receptor is regulated by Rac1, Pak1 and Pak2. EMBO Rep. 9, 356-362 (2008).
55. Mayor, S. & Pagano, R. E. Pathways of clathrin-independent endocytosis. Nature Rev. Mol. Cell Biol. 8, 603-612 (2007).
56. Sabharanjak, S., Sharma, P., Parton, R. G. & Mayor, S. GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Dev. Cell 2, 411-423 (2002).
57. Deinhardt, K., Berninghausen, O., Willison, H. J., Hopkins, C. R. & Schiavo, G. Tetanus toxin is internalized by a sequential clathrin-dependent mechanism initiated within lipid microdomains and independent of epsin1. J. Cell Biol. 174, 459-471 (2006).
58. Schneider, A. et al. Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J. Neurosci. 28, 2874-2882 (2008).
59. Cabiaux, V. pH-sensitive toxins: interactions with membrane bilayers and application to drug delivery. Adv. Drug Deliv. Rev. 56, 987-997 (2004).
60. Caron, N. J., Quenneville, S. P. & Tremblay, J. P. Endosome disruption enhances the functional nuclear delivery of Tat-fusion proteins. Biochem. Biophys. Res. Commun. 319, 12-20 (2004).
61. Asokan, A. & Cho, M. J. Exploitation of intracellular pH gradients in the cellular delivery of macromolecules. J. Pharm. Sci. 91, 903-913 (2002).
62. Vassar, R. Beta-secretase (BACE) as a drug target for Alzheimer's disease. Adv. Drug Deliv. Rev. 54, 1589-1602 (2002).
63. Ehehalt, R., Keller, P., Haass, C., Thiele, C. & Simons, K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113-123 (2003).
64. Ippoliti, R. et al. A chimeric saporin-transferrin conjugate compared to ricin toxin: role of the carrier in intracellular transport and toxicity. FASEB J. 9, 1220-1225 (1995).
65. Wellhoner, H. H., Neville, D. M. Jr, Srinivasachar, K. & Erdmann, G. Uptake and concentration of bioactive macromolecules by K562 cells via the transferrin cycle utilizing an acid-labile transferrin conjugate. J. Biol. Chem. 266, 4309-4314 (1991).
66. Leamon, C. P. & Reddy, J. A. Folate-targeted chemotherapy. Adv. Drug Deliv. Rev. 56, 1127-1141 (2004).
67. Kader, A., Davis, P. J., Kara, M. & Liu, H. Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. J. Control Release 55, 231-243 (1998).
68. Hilgenbrink, A. R. & Low, P. S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci. 94, 2135-2146 (2005).
69. Lubgan, D., Jozwiak, Z., Grabenbauer, G. G. & Distel, L. V. Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells. Cell. Mol. Biol. Lett. 14, 113-127 (2009).
70. Singh, M., Atwal, H. & Micetich, R. Transferrin directed delivery of adriamycin to human cells. Anticancer Res. 18, 1423-1427 (1998).
71. Zhao, X., Li, H. & Lee, R. J. Targeted drug delivery via folate receptors. Expert Opin. Drug Deliv. 5, 309-319 (2008).
72. Gupta, Y., Jain, A., Jain, P. & Jain, S. K. Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells. J. Drug Target 15, 231-240 (2007).
73. Dixit, V., Van den Bossche, J., Sherman, D. M., Thompson, D. H. & Andres, R. P. Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjug. Chem. 17, 603-609 (2006).
74. Beduneau, A. et al. Brain targeting using novel lipid nanovectors. J. Control Release 126, 44-49 (2008).
75. Gupta, Y., Jain, A. & Jain, S. K. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm. Pharmacol. 59, 935-940 (2007).
76. Ulbrich, K., Hekmatara, T., Herbert, E. & Kreuter, J. Transferrin-and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm. 71, 251-256 (2009).
77. Futerman, A. H. & van Meer, G. The cell biology of lysosomal storage disorders. Nature Rev. Mol. Cell Biol. 5, 554-565 (2004).
78. Grabowski, G. A. & Hopkin, R. J. Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annu. Rev. Genomics Hum. Genet. 4, 403-436 (2003).
79. Desnick, R. J., Thorpe, S. R. & Fiddler, M. B. Toward enzyme therapy for lysosomal storage diseases. Physiol. Rev. 56, 57-99 (1976).
80. Sly, W. S. et al. Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors. Proc. Natl Acad. Sci. USA 103, 15172-15177 (2006).
81. Zhu, Y., Li, X., Schuchman, E. H., Desnick, R. J. & Cheng, S. H. Dexamethasone-mediated up-regulation of the mannose receptor improves the delivery of recombinant glucocerebrosidase to Gaucher macrophages. J. Pharmacol. Exp. Ther. 308, 705-711 (2004).
82. Mukherjee, S. & Maxfield, F. R. Lipid and cholesterol trafficking in NPC. Biochim. Biophys. Acta 1685, 28-37 (2004).
83. Liu, B. et al. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/-mouse. Proc. Natl Acad. Sci. USA 106, 2377-2382 (2009).
84. Johannes, L. & Decaudin, D. Protein toxins: intracellular trafficking for targeted therapy. Gene Ther. 12, 1360-1368 (2005).
85. Gariepy, J. The use of Shiga-like toxin 1 in cancer therapy. Crit. Rev. Oncol. Hematol. 39, 99-106 (2001).
86. Furukawa, K. et al. Expression of the Gb3/CD77 synthase gene in megakaryoblastic leukemia cells: implication in the sensitivity to verotoxins. J. Biol. Chem. 277, 11247-11254 (2002).
87. Sillence, D. J. et al. Glucosylceramide modulates membrane traffic along the endocytic pathway. J. Lipid Res. 43, 1837-1845 (2002).
88. Gupta, B., Levchenko, T. S. & Torchilin, V. P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 57, 637-651 (2005).
89. Frankel, A. D. & Pabo, C. O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189-1193 (1988).
90. Elliott, G. & O'Hare, P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88, 223-233 (1997).
91. Wender, P. A. et al. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl Acad. Sci. USA 97, 13003-13008 (2000).
92. Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R. & Brock, R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8, 848-866 (2007).
93. Chen, B., Liu, Q., Zhang, Y., Xu, L. & Fang, X. Transmembrane delivery of the cell-penetrating peptide conjugated semiconductor quantum dots. Langmuir 24, 11866-11871 (2008).
94. Holowka, E. P., Sun, V. Z., Kamei, D. T. & Deming, T. J. Polyarginine segments in block copolypeptides drive both vesicular assembly and intracellular delivery. Nature Mater. 6, 52-57 (2007).
95. Khalil, I. A. et al. Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation. Gene Ther. 11, 636-644 (2004).
96. Futaki, S. et al. Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug. Chem. 12, 1005-1011 (2001).
97. Murthy, N., Robichaud, J. R., Tirrell, D. A., Stayton, P. S. & Hoffman, A. S. The design and synthesis of polymers for eukaryotic membrane disruption. J. Control Release 61, 137-143 (1999).
98. Mastrobattista, E. et al. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J. Biol. Chem. 277, 27135-27143 (2002).
99. Li, W., Nicol, F. & Szoka, F. C. Jr. GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv. Drug Deliv. Rev. 56, 967-985 (2004).
100. Leopold, P. L. & Crystal, R. G. Intracellular trafficking of adenovirus: many means to many ends. Adv. Drug Deliv. Rev. 59, 810-821 (2007).
101. Abrami, L., Lindsay, M., Parton, R. G., Leppla, S. H. & van der Goot, F. G. Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway. J. Cell Biol. 166, 645-651 (2004).
102. Le Blanc, I. et al. Endosome-to-cytosol transport of viral nucleocapsids. Nature Cell Biol. 7, 653-664 (2005).
103. Duncan, R. Designing polymer conjugates as lysosomotropic nanomedicines. Biochem. Soc. Trans. 35, 56-60 (2007).
104. Kreitman, R. J. Recombinant toxins for the treatment of cancer. Curr. Opin. Mol. Ther. 5, 44-51 (2003).
105. Sun, Q., Cai, S. & Peterson, B. R. Selective disruption of early/recycling endosomes: release of disulfide-linked cargo mediated by a N.-alkyl-3beta-cholesterylamine-capped peptide. J. Am. Chem. Soc. 130, 10064-10065 (2008).
106. Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nature Rev. Drug Discov. 8, 129-138 (2009).
107. Rozema, D. B. et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl Acad. Sci. USA 104, 12982-12987 (2007).
108. Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nature Biotech. 26, 561-569 (2008).
109. de Fougerolles, A., Vornlocher, H. P., Maraganore, J. & Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nature Rev. Drug Discov. 6, 443-453 (2007).
110. Berg, K. et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res. 59, 1180-1183 (1999).
111. Kamiya, H., Tsuchiya, H., Yamazaki, J. & Harashima, H. Intracellular trafficking and transgene expression of viral and non-viral gene vectors. Adv. Drug Deliv. Rev. 52, 153-164 (2001).
112. Nabi, I. R. & Le, P. U. Caveolae/raft-dependent endocytosis. J. Cell Biol. 161, 673-677 (2003).
113. Li, S. & Huang, L. Nonviral gene therapy: promises and challenges. Gene Ther. 7, 31-34 (2000).
114. Goula, D. et al. Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther. 5, 1291-1295 (1998).
115. Budker, V., Gurevich, V., Hagstrom, J. E., Bortzov, F. & Wolff, J. A. pH-sensitive, cationic liposomes: a new synthetic virus-like vector. Nature Biotech. 14, 760-764 (1996).
116. Farokhzad, O. C. & Langer, R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv. Drug Deliv. Rev. 58, 1456-1459 (2006).
117. Yu, D. et al. The specific delivery of proteins to human liver cells by engineered bio-nanocapsules. FEBS J. 272, 3651-3660 (2005).
118. Yamada, T. et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nature Biotech. 21, 885-890 (2003).
119. Farokhzad, O. C. & Langer, R. Impact of nanotechnology on drug delivery. ACS Nano 3, 16-20 (2009).
120. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech. 2, 751-760 (2007).
121. Nagaoka, T. et al. Characterization of bio-nanocapsule as a transfer vector targeting human hepatocyte carcinoma by disulfide linkage modification. J. Control Release 11 8, 348-356 (2007).
122. Schroder, T. et al. Peptoidic amino-and guanidinium-carrier systems: targeted drug delivery into the cell cytosol or the nucleus. J. Med. Chem. 51, 376-379 (2008).
123. Sen, N. & Majumder, H. K. Mitochondrion of protozoan parasite emerges as potent therapeutic target: exciting drugs are on the horizon. Curr. Pharm. Des. 14, 839-846 (2008).
124. Muratovska, A., Lightowlers, R. N., Taylor, R. W., Wilce, J. A. & Murphy, M. P. Targeting large molecules to mitochondria. Adv. Drug Deliv. Rev. 49, 189-198 (2001).
125. Pilkington, G. J., Parker, K. & Murray, S. A. Approaches to mitochondrially mediated cancer therapy. Semin. Cancer Biol. 18, 226-235 (2008).
126. Debatin, K. M., Poncet, D. & Kroemer, G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 21, 8786-8803 (2002).
127. Murphy, M. P. Targeting lipophilic cations to mitochondria. Biochim. Biophys. Acta 1777, 1028-1031 (2008).
128. Szeto, H. H. Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Ann. NY Acad. Sci. 1147, 112-121 (2008).
129. Kang, B. H. et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest. 11 9, 454-464 (2009).
130. Kang, B. H. et al. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 131, 257-270 (2007).
131. Di Paolo, G. & De Camilli, P. Phosphoinositides in cell regulation and membrane dynamics. Nature 443, 651-657 (2006).
132. Wymann, M. P. & Schneiter, R. Lipid signalling in disease. Nature Rev. Mol. Cell Biol. 9, 162-176 (2008).
133. Hammond, G. R. & Schiavo, G. Polyphosphoinositol lipids: under-PPInning synaptic function in health and disease. Dev. Neurobiol. 67, 1232-1247 (2007).
134. Trajkovic, K. et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319, 1244-1247 (2008).
135. Lecuyer, E. et al. Global analysis of mRNA localization reveals a prominent role in organizing cellular architecture and function. Cell 131, 174-187 (2007).
136. Besse, F. & Ephrussi, A. Translational control of localized mRNAs: restricting protein synthesis in space and time. Nature Rev. Mol. Cell Biol. 9, 971-980 (2008).
137. Siegel, G. et al. A functional screen implicates microRNA-138-dependent regulation of the depalmitoylation enzyme APT1 in dendritic spine morphogenesis. Nature Cell Biol. 11, 705-716 (2009).
138. Gibbings, D. J., Ciaudo, C., Erhardt, M. & Voinnet, O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nature Cell Biol. 11, 1143-1149 (2009).
139. Lee, Y. S. et al. Silencing by small RNAs is linked to endosomal trafficking. Nature Cell Biol. 11, 1150-1156 (2009).
140. Miyashiro, K. Y., Bell, T. J., Sul, J. Y. & Eberwine, J. Subcellular neuropharmacology: the importance of intracellular targeting. Trends Pharmacol. Sci. 30, 203-211 (2009).
141. Panakova, D., Sprong, H., Marois, E., Thiele, C. & Eaton, S. Lipoprotein particles are required for Hedgehog and Wingless signalling. Nature 435, 58-65 (2005).
142. Fevrier, B., Vilette, D., Laude, H. & Raposo, G. Exosomes: a bubble ride for prions? Traffic 6, 10-17 (2005).
143. Spencer, B. J. & Verma, I. M. Targeted delivery of proteins across the blood-brain barrier. Proc. Natl Acad. Sci. USA 104, 7594-7599 (2007).
144. Eggeling, C. et al. Direct observation of the nanoscale dynamics of membrane lipids in a living cell. Nature 457, 1159-1162 (2009).
145. Fantini, J., Garmy, N., Mahfoud, R. & Yahi, N. Lipid rafts: structure, function and role in, HIV, Alzheimer's and prion diseases. Expert Rev. Mol. Med. 4, 1-22 (2002).
146. Nayak, D. P., Hui, E. K. & Barman, S. Assembly and budding of influenza virus. Virus Res. 106, 147-165 (2004).
147. + T cells. J. Virol. 76, 4709-4722 (2002).
148. Manes, S. et al. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep. 1, 190-196 (2000).
149. Nguyen, D. H. & Taub, D. D. Targeting lipids to prevent HIV infection. Mol. Interv. 4, 318-320 (2004).
150. Khanna, K. V. et al. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J. Clin. Invest. 109, 205-211 (2002).
151. Cranage, M. et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 5, e157; discussion e157 (2008).
152. Verma, S. P. HIV: a raft-targeting approach for prevention and therapy using plant-derived compounds (review). Curr. Drug Targets. 10, 51-59 (2009).
153. Scheiffele, P., Rietveld, A., Wilk, T. & Simons, K. Influenza viruses select ordered lipid domains during budding from the plasma membrane. J. Biol. Chem. 274, 2038-2044 (1999).
154. Ali, A., Avalos, R. T., Ponimaskin, E. & Nayak, D. P. Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J. Virol. 74, 8709-8719 (2000).
155. Murphy, S. C. et al. Lipid rafts and malaria parasite infection of erythrocytes. Mol. Membr. Biol. 23, 81-88 (2006).
156. Samuel, B. U. et al. The role of cholesterol and glycosylphosphatidylinositol-anchored proteins of erythrocyte rafts in regulating raft protein content and malarial infection. J. Biol. Chem. 276, 29319-29329 (2001).
157. Ferguson, M. A. Glycosylphosphatidylinositol biosynthesis validated as a drug target for African sleeping sickness. Proc. Natl Acad. Sci. USA 97, 10673-10675 (2000).
158. Cheng, H. et al. Mechanisms of Disease: new therapeutic strategies for Alzheimer's disease-targeting APP processing in lipid rafts. Nature Clin. Pract. Neurol. 3, 374-382 (2007).
159. Hooper, N. M. Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. Biochem. Soc. Trans. 33, 335-338 (2005).
160. Holowka, D. et al. Lipid segregation and IgE receptor signaling: a decade of progress. Biochim. Biophys. Acta 1746, 252-259 (2005).
161. Gidwani, A., Brown, H. A., Holowka, D. & Baird, B. Disruption of lipid order by short-chain ceramides correlates with inhibition of phospholipase D and downstream signaling by FceRI. J. Cell Sci. 11 6, 3177-3187 (2003).
162. Morrissey, D. V. et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotech. 23, 1002-1007 (2005).
163. Aouadi, M. et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458, 1180-1184 (2009).
164. Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotech. 25, 1149-1157 (2007).
165. Mukherjee, S., Soe, T. T. & Maxfield, F. R. Endocytic sorting of lipid analogues differing solely in the chemistry of their hydrophobic tails. J. Cell Biol. 144, 1271-1284 (1999).
166. van Meer, G. Cellular lipidomics. EMBO J. 24, 3159-3165 (2005).
167. Fivaz, M. et al. Differential sorting and fate of endocytosed GPI-anchored proteins. EMBO J. 21, 3989-4000 (2002).
168. van Meer, G. & Sprong, H. Membrane lipids and vesicular traffic. Curr. Opin. Cell Biol. 16, 373-378 (2004).
169. Pellizzari, A., Pang, H. & Lingwood, C. A. Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. Biochemistry 31, 1363-1370 (1992).
170. Kiarash, A., Boyd, B. & Lingwood, C. A. Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. J. Biol. Chem. 269, 11138-11146 (1994).
171. Koivusalo, M., Jansen, M., Somerharju, P. & Ikonen, E Endocytic trafficking of sphingomyelin depends on its acyl chain length. Mol. Biol. Cell 18, 5113-5123 (2007).
172. Boonyarattanakalin, S., Martin, S. E., Dykstra, S. A. & Peterson, B. R. Synthetic mimics of small Mammalian cell surface receptors. J. Am. Chem. Soc. 126, 16379-16386 (2004).